Targeted radiosensitization by the Chk1 inhibitor SAR-020106

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Checkpoint kinase 1 (Chk1) is crucial for cell cycle regulation and DNA damage response.
• Radiotherapy is a cornerstone of cancer treatment, but resistance remains a challenge.
• p53 tumor suppressor pathway plays a critical role in cellular response to DNA damage.

Purpose of the Study:

• To evaluate the efficacy of a potent Chk1 inhibitor, SAR-020106, in combination with radiation therapy.
• To investigate the mechanisms underlying the combined treatment's effects on tumor cells.
• To assess the therapeutic potential in preclinical cancer models.

Main Methods:

• In vitro colony formation and mechanistic assays were performed.
• In vivo efficacy was tested using a human head-and-neck cancer xenograft model.
• Cell cycle progression, apoptosis, DNA repair, and aneuploidy were analyzed.

Main Results:

• SAR-020106 suppressed radiation-induced G2/M arrest and reduced clonogenic survival specifically in p53-deficient cells.
• While promoting mitotic entry post-irradiation in all cells, p53-deficient cells underwent apoptosis or aneuploidy, unlike p53 wild-type cells.
• Homologous recombination DNA repair was inhibited by the combination therapy in all cell lines.
• Increased pan-γH2AX-positive apoptotic cells were observed exclusively in p53-deficient lines.
• The combination demonstrated significant efficacy in a head-and-neck cancer xenograft model.

Conclusions:

• The Chk1 inhibitor SAR-020106 acts as a potent radiosensitizer in tumor cells lacking functional p53.
• This combination strategy holds promise for treating p53-deficient cancers.
• Targeting Chk1 in conjunction with radiation offers a potential therapeutic approach for specific tumor types.